Spots Global Cancer Trial Database for vinorelbine
Every month we try and update this database with for vinorelbine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma | NCT00256282 | Metastatic Mela... | Vinorelbine Docetaxel Sargramostim | 18 Years - | University of California, Irvine | |
| Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | NCT02567435 | Alveolar Rhabdo... Botryoid-Type E... Embryonal Rhabd... Rhabdomyosarcom... Sclerosing Rhab... Spindle Cell Rh... | Cyclophosphamid... Dactinomycin Irinotecan Hydr... Laboratory Biom... Questionnaire A... Radiation Thera... Temsirolimus Vincristine Sul... Vinorelbine | - 40 Years | National Cancer Institute (NCI) | |
| An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease | NCT03770299 | Non-Small Cell ... Non-Small-Cell ... Circulating Tum... | Nivolumab Vinorelbine Gemcitabine Docetaxel Pemetrexed Cisplatin Carboplatin Paclitaxel Observation | 18 Years - | Bristol-Myers Squibb | |
| Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC | NCT01848613 | Non-small Cell ... | Vinorelbine | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer | NCT00401427 | Metastatic Brea... | trastuzumab vinorelbine | 18 Years - | National Cancer Institute, Naples | |
| Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) | NCT02610140 | Mesothelioma | Anetumab ravtan... Vinorelbine | 18 Years - | Bayer | |
| LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment | NCT01125566 | Breast Neoplasm... | BIBW 2992 trastuzumab vinorelbine vinorelbine | 18 Years - | Boehringer Ingelheim | |
| Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer | NCT00705549 | Non-Small-Cell ... | Gemcitabine Cisplatin Docetaxel Cisplatin Vinorelbine Pemetrexate | 18 Years - | Hellenic Oncology Research Group | |
| Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients | NCT01749072 | Non-small Cell ... Effects of Chem... | Gefitinib group Vinorelbine, If... | 18 Years - 70 Years | Peking Union Medical College Hospital | |
| Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer | NCT00151086 | Prostate Cancer | Estramustine Vinorelbine | 18 Years - | University of Michigan Rogel Cancer Center | |
| Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer | NCT00193362 | Lung Cancer | Paclitaxel Carboplatin Gemcitabine Vinorelbine | 18 Years - | SCRI Development Innovations, LLC | |
| Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation | NCT01683175 | Non-small Cell ... | Erlotinib cis-platinum Vinorelbine | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | NCT05999994 | Neoplasms Child Adolescent | Ramucirumab Cyclophosphamid... Vinorelbine Gemcitabine Docetaxel Abemaciclib Irinotecan Temozolomide | 1 Year - 39 Years | Eli Lilly and Company | |
| Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation | NCT01683175 | Non-small Cell ... | Erlotinib cis-platinum Vinorelbine | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection | NCT02223611 | Non-small Cell ... Non-small Cell ... | S1 capsule Vinorelbine | 18 Years - 75 Years | Hebei Medical University Fourth Hospital | |
| Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease | NCT00388349 | Hodgkin Disease Hodgkin's Lymph... Lymphoma | Gemcitabine Vinorelbine Carmustine Etoposide Cyclophosphamid... Autologous HCT | 18 Years - 70 Years | Stanford University | |
| Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies | NCT00477035 | Leukemia Multiple Myelom... | CIK cells etoposide bcnu cyclophosphamid... gemcitabine vinorelbine melphalan | 18 Years - 75 Years | Stanford University | |
| Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | NCT02892123 | HER2-expressing... | ZW25 (Zanidatam... Paclitaxel Capecitabine Vinorelbine Tucatinib Tucatinib | 18 Years - | Jazz Pharmaceuticals | |
| Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer | NCT01254136 | Breast Cancer | INCB007839 300m... Trastuzumab Vinorelbine | 18 Years - | Incyte Corporation | |
| Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer | NCT04143906 | Metastatic Brea... | Vinorelbine Gemcitabine Carboplatin | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer | NCT00431704 | Metastatic Brea... | vinorelbine carboplatin trastuzumab | 18 Years - 75 Years | National Cancer Institute, Naples | |
| A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer | NCT03997539 | Metastatic Brea... | Pyrotinib Treatment of ph... vinorelbine | 18 Years - 70 Years | Sun Yat-sen University | |
| MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung Cancer | NCT00401492 | Non Small Cell ... | gemcitabine pro... cisplatin vinorelbine | 70 Years - | National Cancer Institute, Naples | |
| The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer | NCT00345059 | Advanced Non-Sm... | docetaxel vinorelbine gemcitabine capecitabine | - 75 Years | National Cancer Institute, Naples | |
| Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer | NCT00686959 | Non Small Cell ... | Pemetrexed Cisplatin Etoposide Vinorelbine Paclitaxel Carboplatin Thoracic Radiat... | 18 Years - | Eli Lilly and Company | |
| Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer | NCT00441740 | Non Small Cell ... | Vinorelbine Gemcitabine Docetaxel Gemcitabine | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection | NCT02223611 | Non-small Cell ... Non-small Cell ... | S1 capsule Vinorelbine | 18 Years - 75 Years | Hebei Medical University Fourth Hospital | |
| Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer | NCT01439191 | Metastatic Brea... | humanized anti-... Vinorelbine | 18 Years - 70 Years | Shanghai CP Guojian Pharmaceutical Co., Ltd. | |
| S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer | NCT00015938 | Breast Cancer | filgrastim docetaxel vinorelbine | 18 Years - | SWOG Cancer Research Network | |
| Vinorelbine and Gemcitabine in Myeloma | NCT02791373 | Multiple Myelom... Amyloidosis | Vinorelbine Gemcitabine | 18 Years - 75 Years | Insel Gruppe AG, University Hospital Bern | |
| Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer | NCT03801304 | Non-small Cell ... | Atezolizumab Vinorelbine | 18 Years - | University Hospital, Brest | |
| Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease | NCT00388349 | Hodgkin Disease Hodgkin's Lymph... Lymphoma | Gemcitabine Vinorelbine Carmustine Etoposide Cyclophosphamid... Autologous HCT | 18 Years - 70 Years | Stanford University | |
| Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis | NCT06137651 | Breast Carcinom... Metastatic Mali... Metastatic Mali... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Radiation Thera... Resection Trotabresib Vinorelbine | 18 Years - | Northwestern University | |
| Vinorelbine in Advanced BRAF-like Colon Cancer | NCT03482362 | Colon Cancer | Vinorelbine Tar... | 18 Years - | The Netherlands Cancer Institute | |
| The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer | NCT00215930 | Carcinoma, Non-... | Vinorelbine Docetaxel Gemcitabine Carboplatin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas | NCT03161054 | Aggressive Non-... | Prednisone Vinorelbine Etoposide Cyclophosphamid... Rituximab | 65 Years - | Fondazione Italiana Linfomi - ETS | |
| Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine | NCT04850625 | Breast Cancer | 18 Years - | Fudan University | ||
| Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer | NCT00441740 | Non Small Cell ... | Vinorelbine Gemcitabine Docetaxel Gemcitabine | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Chemotherapy and G-CSF for Mobilization | NCT03442673 | Multiple Myelom... | Vinorelbine Gemcitabine G-CSF | 18 Years - | Insel Gruppe AG, University Hospital Bern | |
| Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC) | NCT01687439 | Non-small Cell ... | Endostar Vinorelbine Cisplatin Radiotherapy | 18 Years - | Fudan University | |
| A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer | NCT00140140 | Stage IV (Metas... | ABI-007 vinorelbine Trastuzumab G-CSF | 18 Years - | Celgene | |
| Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer | NCT00724386 | Breast Cancer | Paclitaxel Vinorelbine Filgrastim Radiation | 18 Years - | University of Chicago | |
| Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | NCT03618550 | Hodgkin Lymphom... Relapsed or Ref... | pembrolizumab gemcitabine vinorelbine liposomal doxor... Stem cell mobil... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM | NCT02555007 | Non Small Cell ... Malignant Pleur... | Vinorelbine | 18 Years - | Assistance Publique Hopitaux De Marseille | |
| A Phase 3, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | NCT06435429 | Metastatic HER2... | Zanidatamab Trastuzumab Eribulin Vinorelbine Gemcitabine Capecitabine | 18 Years - | Jazz Pharmaceuticals | |
| Phase II Iressa + Irradiation Followed by Chemo in NSCLC | NCT00333294 | Non-Small Cell ... | Gefitinib Radiation thera... Cisplatin Vinorelbine | 18 Years - 75 Years | AstraZeneca | |
| Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | NCT03901339 | Metastatic Brea... | Sacituzumab Gov... Eribulin Capecitabine Gemcitabine Vinorelbine | 18 Years - | Gilead Sciences | |
| GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial | NCT02319577 | Non Small Cell ... | oral vinorelbin... Gefitinib | 18 Years - | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | |
| A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) | NCT02998528 | Non Small Cell ... | Nivolumab Cisplatin Vinorelbine Gemcitabine Docetaxel Pemetrexed Carboplatin Paclitaxel Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | NCT06229067 | Breast Cancer Triple Negative... | Adebrelimab Vinorelbine Cyclophosphamid... Capecitabine | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor | NCT04145349 | Desmoplastic Sm... | Ramucirumab Cyclophosphamid... Vinorelbine | 12 Months - 29 Years | Eli Lilly and Company | |
| Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer | NCT00176488 | Breast Cancer | epirubicin vinorelbine | 21 Years - 120 Years | Rutgers, The State University of New Jersey | |
| Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma | NCT01884428 | Hodgkin's Lymph... | panobinostat Ifosfamide Gemcitabine Vinorelbine Prednisolone | 18 Years - 65 Years | Istituto Clinico Humanitas | |
| Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer | NCT00193089 | Breast Cancer | Docetaxel Vinorelbine Trastuzumab | 18 Years - | SCRI Development Innovations, LLC | |
| A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer | NCT02352948 | Non - Small Cel... | MEDI4736 (durva... Vinorelbine Gemcitabine Erlotinib MEDI4736 (durva... tremelimumab (a... | 18 Years - 130 Years | AstraZeneca | |
| A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer | NCT03811418 | Advanced Breast... HER2-positive B... | Trastuzumab Pertuzumab Vinorelbine Docetaxel | 18 Years - | iOMEDICO AG | |
| Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer | NCT00146549 | Breast Cancer Stage IV Breast... | Trastuzumab Vinorelbine Paclitaxel Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| Vinorelbine for Recurrent ALCL-2017 | NCT03443128 | Anaplastic Larg... Vinorelbine | Vinorelbine | - 18 Years | Children's Cancer Group, China | |
| Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine | NCT04850625 | Breast Cancer | 18 Years - | Fudan University | ||
| Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer | NCT00694200 | Breast Cancer | Vinorelbine Bevacizumab | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer | NCT02985658 | Metastatic Brea... Triple-Negative... | Veliparib Cisplatin Vinorelbine | 18 Years - | University of Washington | |
| Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | NCT03901339 | Metastatic Brea... | Sacituzumab Gov... Eribulin Capecitabine Gemcitabine Vinorelbine | 18 Years - | Gilead Sciences | |
| Chemoradiotherapy in Patients With Localised Lung Cancer | NCT00193921 | Non Small Cell ... | Vinorelbine High dose Radio... Gemcitabine Cisplatin High Dose Radio... | 18 Years - | Trans Tasman Radiation Oncology Group | |
| A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer. | NCT00773188 | Non-Squamous No... | bevacizumab [Av... cisplatin vinorelbine | 18 Years - | Hoffmann-La Roche | |
| An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1) | NCT01684111 | Carcinoma, Non-... | BIBF 1120 Vinorelbine | 71 Years - | Aktion Bronchialkarzinom e.V. | |
| A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | NCT06081959 | Metastatic Brea... | SKB264 Eribulin Capecitabine Gemcitabine Vinorelbine | 18 Years - 75 Years | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | |
| Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer | NCT00430001 | Breast Cancer | docetaxel vinorelbine trastuzumab | 18 Years - 74 Years | Danish Breast Cancer Cooperative Group | |
| Trastuzumab & Pertuzumab Followed by T-DM1 in MBC | NCT01835236 | Metastatic Brea... | Trastuzumab Pertuzumab Paclitaxel Vinorelbine T-DM1 | 18 Years - | Swiss Group for Clinical Cancer Research | |
| S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer | NCT00015938 | Breast Cancer | filgrastim docetaxel vinorelbine | 18 Years - | SWOG Cancer Research Network | |
| Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients | NCT00128310 | Breast Cancer Neoplasm Metast... | Vinorelbine Gemcitabine | 18 Years - | Spanish Breast Cancer Research Group | |
| Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC) | NCT01687439 | Non-small Cell ... | Endostar Vinorelbine Cisplatin Radiotherapy | 18 Years - | Fudan University | |
| Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer | NCT00705549 | Non-Small-Cell ... | Gemcitabine Cisplatin Docetaxel Cisplatin Vinorelbine Pemetrexate | 18 Years - | Hellenic Oncology Research Group | |
| The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | NCT03414658 | Breast Cancer | Vinorelbine Trastuzumab Avelumab Utomilumab | 18 Years - | Dana-Farber Cancer Institute | |
| Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer | NCT04681911 | Breast Cancer | Inetetamab Pyrotinib Capecitabine Gemcitabine Vinorelbine Carboplatin Albumin paclita... Eribulin | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC) | NCT00629148 | Breast Cancer Metastasis, Neo... | Vinorelbine and... Vinorelbine and... | 18 Years - 70 Years | Fudan University | |
| Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer | NCT02985203 | Lung Neoplasm M... | Vinorelbine Ora... | 18 Years - | Guangdong Association of Clinical Trials | |
| A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer | NCT00140140 | Stage IV (Metas... | ABI-007 vinorelbine Trastuzumab G-CSF | 18 Years - | Celgene | |
| S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer | NCT00015938 | Breast Cancer | filgrastim docetaxel vinorelbine | 18 Years - | SWOG Cancer Research Network | |
| The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy | NCT03423849 | Breast Cancer Chemotherapy Ef... Disease-free Su... | Vinorelbine Gemcitabine Cisplatin Capecitabine | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease | NCT00364676 | Tumors Hodgkins Diseas... Non-Hodgkins Ly... | VLI VLI | 18 Years - | Spectrum Pharmaceuticals, Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
